924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Merit Medical said preliminary, unaudited fourth-quarter 2025 revenue was in the range of $389 million to $395 million, up about 10% to 11% from a year earlier, or 8% to 10% in constant currency. The company also named F. Ann Millner as Board Chair after founder Fred P. Lampropoulos resigned as director and Chair, which matters to shareholders because the company's leadership is changing while full 2025 results and 2026 guidance are still pending.
Preliminary Q4 2025 revenue of about $389 million to $395 million, up about 10% to 11% year over year; constant currency growth of about 8% to 10%
Lampropoulos resigned as director and Chair effective January 4, 2026, citing personal reasons, and is not leaving over any dispute or financial reporting matter
F. Ann Millner, formerly Lead Independent Director, became Chair effective January 5, 2026; the board also reduced its size from eleven to ten members
Full 2025 results and fiscal 2026 guidance are scheduled for release after the close on February 24, 2026
Greenbrier reported first-quarter fiscal 2026 results for the period ended November 30, 2025, with revenue of $706.1 million, down from $875.9 million a year earlier, and diluted EPS of $1.14, down from $1.72. The company reiterated its fiscal 2026 operating metrics and updated its capital expenditure guidance, and its board approved a $0.32 quarterly dividend.
Revenue of $706.1 million vs. $875.9 million in the prior-year quarter; Manufacturing revenue was $657.0 million vs. $830.9 million
Net earnings attributable to Greenbrier of $36.4 million, or $1.14 per diluted share, vs. $55.3 million, or $1.72, a year earlier
Operating cash flow of $76.2 million vs. a use of $65.1 million in the prior-year quarter; fiscal 2026 EPS guidance of $3.75 to $4.75 reiterated
Quarterly dividend of $0.32 per share payable February 17, 2026, to shareholders of record as of January 27, 2026
WD-40 Company reported first-quarter fiscal 2026 results for the quarter ended November 30, 2025. Net sales rose 1% to $154.4 million, but operating income fell 7% to $23.3 million and diluted earnings per share fell 8% to $1.28, with currency translation adding about $3.4 million to sales. Management reaffirmed its fiscal 2026 guidance and said it expects results toward the mid-to-high end of its ranges.
Net sales were $154.4 million, up 1%; on a constant currency basis, net sales were $151.0 million, down 2%.
Net income was $17.5 million, down 8%, and diluted EPS was $1.28 versus $1.39 a year earlier.
Maintenance product sales in direct markets rose 8%, while Asia-Pacific net sales fell 10%.
Fiscal 2026 guidance was reaffirmed, including operating income of $103 million to $110 million and diluted EPS of $5.75 to $6.15.
Pacira BioSciences reported preliminary, unaudited total revenue of $726.4 million for 2025, compared with $701.0 million in 2024, with fourth-quarter EXPAREL net product sales of $155.8 million. The figures are subject to adjustment, and the company expects to report complete fourth-quarter and full-year 2025 results and financial guidance later in the first quarter of 2026.
Full-year 2025 total revenue of $726.4 million, compared with $701.0 million in 2024.
Full-year EXPAREL net product sales of $575.1 million, compared with $549.0 million, with volume growth of 6 percent.
During the fourth quarter of 2025, the company repurchased 2.0 million shares for $50.0 million; $150.0 million remains on its authorization, which expires December 31, 2026.
CMC reported first-quarter fiscal 2026 net earnings of $177.3 million, or $1.58 per diluted share, on net sales of $2.1 billion, compared with a net loss of $175.7 million in the prior-year quarter, which included a $265.0 million litigation charge. Adjusted earnings were $206.2 million, or $1.84 per diluted share, versus $0.76 a year earlier. Management expects second-quarter core EBITDA to decline modestly from first-quarter levels due to seasonal slowdown, partly offset by the recently acquired precast businesses.
Net earnings of $177.3 million, or $1.58 per diluted share, versus a net loss of $175.7 million, or $1.54 per diluted share, a year earlier
Adjusted earnings of $206.2 million, or $1.84 per diluted share, versus $86.9 million, or $0.76 per diluted share, in the prior-year period
Second-quarter fiscal 2026 consolidated core EBITDA expected to decline modestly from first-quarter levels
Quarterly dividend of $0.18 per share declared January 5, 2026, payable February 2, 2026
Xencor preliminarily estimates cash, cash equivalents and marketable debt securities of approximately $611 million as of December 31, 2025, down from $706.7 million a year earlier. The company says it expects cash to fund research and development programs and operations through 2028, but the figures are unaudited and may change after year-end closing and audit procedures.
Preliminary cash, cash equivalents and marketable debt securities: approximately $611 million as of December 31, 2025, versus $706.7 million as of December 31, 2024
Company expects cash to fund research and development and operations through 2028, based on current operating plans
Figures are unaudited and not reviewed by the independent auditor; actual results may differ
Press release also outlines 2026 milestones, including a Phase 1 study start for XmAb412 in 2H26 and clinical data updates across several programs
Acuity Inc. reported fiscal first-quarter 2026 results for the quarter ended November 30, 2025. Net sales rose 20.2% to $1.14 billion, operating profit rose 20.3% to $160.4 million, and diluted EPS rose 14.0% to $3.82. The release does not include updated financial guidance, and part of the sales growth comes from three months of QSC performance within the Acuity Intelligent Spaces segment.
Net sales were $1,143.7 million versus $951.6 million a year earlier, an increase of $192.1 million or 20.2%.
Diluted EPS was $3.82 versus $3.35; adjusted diluted EPS was $4.69 versus $3.97.
Acuity Intelligent Spaces net sales were $257.4 million versus $73.5 million, including three months of QSC performance.
During the quarter the company repurchased about 77,000 shares for about $28 million and repaid $100.0 million of term-loan borrowings.
Lindsay Corporation reported first-quarter fiscal 2026 results for the period ended November 30, 2025, with revenue down 6% and net earnings down 4% from a year earlier. Irrigation sales fell 9% on weaker North America and international demand, while Infrastructure revenue rose 17%. The company also disclosed a $80 million supply agreement in the Middle East and North Africa region signed after quarter-end and a new share repurchase authorization of up to $150 million.
Total revenues were $155.8 million, down $10.5 million, or 6%, from $166.3 million; operating income was $19.6 million, down 6%.
Diluted EPS was $1.54 versus $1.57; net earnings were $16.5 million versus $17.2 million.
Irrigation revenue fell 9% to $133.4 million, while Infrastructure revenue rose 17% to $22.4 million.
The board authorized a new share repurchase program of up to $150 million; the company repurchased $30.3 million of shares in the quarter.
TD SYNNEX reported fiscal fourth-quarter 2025 results for the period ended November 30, 2025, with revenue of $17.4 billion, up 9.7% year over year and above the high end of its outlook. GAAP diluted EPS rose to $3.04 from $2.29, and non-GAAP diluted EPS was $3.83, up 24.0%. The company also declared a $0.48 quarterly dividend, up 9% year over year, and guided fiscal first-quarter 2026 non-GAAP diluted EPS to $3.00 to $3.50.
Q4 FY25 revenue was $17.4 billion, up 9.7%, and above the high end of the company's outlook; up 7.5% in constant currency.
GAAP diluted EPS was $3.04 versus $2.29; non-GAAP diluted EPS was $3.83 versus $3.09.
Q1 FY26 outlook: revenue of $15.1 to $15.9 billion and non-GAAP diluted EPS of $3.00 to $3.50.
Quarterly dividend of $0.48 per share, payable January 30, 2026, to holders of record as of January 16, 2026.
Simply Good Foods reported fiscal first quarter 2026 results, with net sales of $340.2 million, down 0.3% year over year, and net income of $25.3 million, down 33.7%. Adjusted EBITDA fell 20.6% to $55.6 million, and gross margin declined 590 basis points to 32.3%, driven by input inflation and tariff costs. The company reaffirmed its full-year fiscal 2026 outlook and raised its share repurchase authorization by $200 million, which matters to shareholders because profit fell sharply while the company kept its guidance and returned cash through buybacks.
Net sales of $340.2 million vs. $341.3 million; Quest grew 9.6% while Atkins fell 16.5% and OWYN fell 3.3%
Net income of $25.3 million vs. $38.1 million; diluted EPS of $0.26 vs. $0.38; adjusted diluted EPS of $0.39 vs. $0.49
Fiscal 2026 outlook reaffirmed: net sales -2% to +2%, gross margins down 100 to 150 basis points, adjusted EBITDA -4% to +1%
Board approved a $200 million increase to the repurchase program on January 6, 2026; about $224 million is available
Neogen reported fiscal 2026 second-quarter revenue of $224.7 million, down 2.8% from a year earlier, though core revenue rose 2.9%. The net loss narrowed to $15.9 million from $456.3 million a year earlier, which included a goodwill impairment, but adjusted net income fell to $22.6 million from $24.4 million. The company raised its fiscal 2026 revenue outlook to $845 million to $855 million and its adjusted EBITDA outlook to about $175 million.
Revenue was $224.7 million, down 2.8% from $231.3 million; core revenue rose 2.9%, while divestitures and discontinued product lines reduced revenue by 6.6%.
Net loss was $15.9 million, or $(0.07) per diluted share, versus a $456.3 million loss a year earlier that included a $461.4 million goodwill impairment.
Adjusted EBITDA was $48.7 million, down from $51.4 million; gross margin was 47.5%, down from 49.0%, citing tariff costs, inventory write-offs and product mix.
For fiscal 2026, revenue is now expected at $845 million to $855 million and adjusted EBITDA at approximately $175 million.
RPM reported fiscal 2026 second-quarter results for the quarter ended November 30, 2025, with record sales of $1.91 billion, up 3.5%, but net income attributable to stockholders fell 12.0% to $161.2 million and adjusted diluted EPS fell 13.7% to $1.20. The company said a slower demand environment prompted SG&A-focused optimization actions expected to save about $100 million annually once fully implemented, and it gave mid-single-digit sales growth outlooks for both the third and fourth quarters.
Second-quarter net sales were $1,909,895 thousand, up 3.5%, with a 0.5% organic decline and 3.4% growth from acquisitions.
Diluted EPS was $1.26 versus $1.42 a year earlier; adjusted EBIT was $226.6 million, down 11.2%.
Cost savings of about $100 million annually: roughly $5 million expected in Q3 fiscal 2026, an incremental $20 million in Q4 fiscal 2026 and an incremental $75 million in fiscal 2027.
Outlook: Q3 fiscal 2026 sales expected to rise in the mid-single-digit range and adjusted EBIT up mid- to high-single digits; Q4 sales up mid-single digits and adjusted EBIT up low- to high-single digits.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.